Form 4: AEON Biopharma Director Palmisano Receives Stock Awards

Director Robert J. Palmisano receives stock options and restricted stock units from AEON Biopharma.

Summary

• Robert J. Palmisano, a director of AEON Biopharma, received 36,021 shares of Class A Common Stock on August 31, 2024.
• These shares were awarded as restricted stock units, vesting fully on the second anniversary of the grant date, contingent upon continued service.
• Palmisano also received stock options for 96,210 shares of Class A Common Stock, exercisable in monthly installments over 18 months following the grant date, also contingent upon continued service.
• The exercise price for the stock options is $0.83.
• Following these transactions, Palmisano directly owns 36,021 shares and 96,210 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and restricted stock units to a director is a common practice and generally viewed as a positive sign, aligning the director's interests with the company's performance.

Positives

• The grant of stock options and restricted stock units to a director aligns their interests with the long-term success of the company.
• The vesting schedules incentivize continued service and commitment from the director.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's future prospects.

Stakeholder Impact

• Shareholders may view the granting of stock options and restricted stock units as a positive sign, aligning the director's interests with the company's performance.
• The director is incentivized to contribute to the company's success to realize the value of the stock options and restricted stock units.

Key Dates

Keywords

AEON Biopharma, Robert Palmisano, stock options, restricted stock units, Form 4, director, beneficial ownership, securities